245 related articles for article (PubMed ID: 29807397)
21. A Multifactorial Comparison of Ternary Combinations of Essential Oils in Topical Preparations to Current Antibiotic Prescription Therapies for the Control of Acne Vulgaris-Associated Bacteria.
Owen L; Grootveld M; Arroo R; Ruiz-Rodado V; Price P; Laird K
Phytother Res; 2017 Mar; 31(3):410-417. PubMed ID: 28124400
[TBL] [Abstract][Full Text] [Related]
22. Antibiotic resistance of Propionibacterium acnes in acne vulgaris.
Swanson JK
Dermatol Nurs; 2003 Aug; 15(4):359-62. PubMed ID: 14515616
[TBL] [Abstract][Full Text] [Related]
23. A Polycation Antimicrobial Peptide Mimic without Resistance Buildup against Propionibacterium Acnes.
Nair SS; Zolotarskaya OY; Beckwith MJ; Ohman DE; Wynne KJ
Macromol Biosci; 2017 Sep; 17(9):. PubMed ID: 28605136
[TBL] [Abstract][Full Text] [Related]
24. A Rationally Designed Multifunctional Antibiotic for the Treatment of Drug-Resistant Acne.
Ghosh S; Sinha M; Bhattacharyya A; Sadhasivam S; Megha J; Reddy S; Saini S; Singh H; Kumar D; Kaur SP; Mishra M; Usharani D; Ghosh S; Sengupta S
J Invest Dermatol; 2018 Jun; 138(6):1400-1408. PubMed ID: 29409921
[TBL] [Abstract][Full Text] [Related]
25. Lactobacillus paraplantarum THG-G10 as a potential anti-acne agent with anti-bacterial and anti-inflammatory activities.
Cha H; Kim SK; Kook M; Yi TH
Anaerobe; 2020 Aug; 64():102243. PubMed ID: 32712375
[TBL] [Abstract][Full Text] [Related]
26. In-vitro evaluation of marine derived fungi against Cutibacterium acnes.
Agrawal S; Adholeya A; Barrow CJ; Deshmukh SK
Anaerobe; 2018 Feb; 49():5-13. PubMed ID: 29100929
[TBL] [Abstract][Full Text] [Related]
27. Antibiotic resistance in the topical treatment of acne vulgaris.
Leyden JJ
Cutis; 2004 Jun; 73(6 Suppl):6-10. PubMed ID: 15228128
[TBL] [Abstract][Full Text] [Related]
28. An investigation of antioxidant and anti-inflammatory activities from blood components of Crocodile (Crocodylus siamensis).
Phosri S; Mahakunakorn P; Lueangsakulthai J; Jangpromma N; Swatsitang P; Daduang S; Dhiravisit A; Thammasirirak S
Protein J; 2014 Oct; 33(5):484-92. PubMed ID: 25216803
[TBL] [Abstract][Full Text] [Related]
29. Anti Propionibacterium acnes activity of rhodomyrtone, an effective compound from Rhodomyrtus tomentosa (Aiton) Hassk. leaves.
Saising J; Voravuthikunchai SP
Anaerobe; 2012 Aug; 18(4):400-4. PubMed ID: 22626672
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of the antimicrobial peptide BLP-7 against Propionibacterium acnes and its anti-inflammatory effect on acne vulgaris.
Wu Y; Qiang Y; Cao K; Zhang W; Zhang G
Toxicon; 2020 Sep; 184():109-115. PubMed ID: 32540219
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effects of bee venom on Propionibacterium acnes-induced inflammatory skin disease in an animal model.
An HJ; Lee WR; Kim KH; Kim JY; Lee SJ; Han SM; Lee KG; Lee CK; Park KK
Int J Mol Med; 2014 Nov; 34(5):1341-8. PubMed ID: 25215662
[TBL] [Abstract][Full Text] [Related]
32. Antibacterial activity of Thai herbal extracts on acne involved microorganism.
Niyomkam P; Kaewbumrung S; Kaewnpparat S; Panichayupakaranant P
Pharm Biol; 2010 Apr; 48(4):375-80. PubMed ID: 20645714
[TBL] [Abstract][Full Text] [Related]
33. MLST typing of antimicrobial-resistant Propionibacterium acnes isolates from patients with moderate to severe acne vulgaris.
Giannopoulos L; Papaparaskevas J; Refene E; Daikos G; Stavrianeas N; Tsakris A
Anaerobe; 2015 Feb; 31():50-4. PubMed ID: 25451716
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility of Propionibacterium acnes and Staphylococcus epidermidis to killing by MPO-halide system products. Implication for taurine bromamine as a new candidate for topical therapy in treating acne vulgaris.
Marcinkiewicz J; Biedroń R; Białecka A; Kasprowicz A; Mak M; Targosz M
Arch Immunol Ther Exp (Warsz); 2006; 54(1):61-8. PubMed ID: 16642259
[TBL] [Abstract][Full Text] [Related]
35. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea.
Song M; Seo SH; Ko HC; Oh CK; Kwon KS; Chang CL; Kim MB
J Dermatol; 2011 Jul; 38(7):667-73. PubMed ID: 21352337
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents.
Nishijima S; Kurokawa I; Kawabata S
J Int Med Res; 1996; 24(6):473-7. PubMed ID: 8959531
[TBL] [Abstract][Full Text] [Related]
37. Topical acne treatments in Europe and the issue of antimicrobial resistance.
Leccia MT; Auffret N; Poli F; Claudel JP; Corvec S; Dreno B
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1485-92. PubMed ID: 25677763
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris.
Kurokawa I; Nishijima S; Kawabata S
Eur J Dermatol; 1999; 9(1):25-8. PubMed ID: 9920982
[TBL] [Abstract][Full Text] [Related]
39. Zolav(®) (a p-carboethoxy-tristyrylbenzene derivative) [corrected]: a new antibiotic for the treatment of acne.
Dinant A; Boulos RA
Drug Des Devel Ther; 2016; 10():1235-42. PubMed ID: 27042015
[TBL] [Abstract][Full Text] [Related]
40. Topically applied antibiotics in acne vulgaris: clinical response and suppression of Corynebacterium acnes in open comedones.
Resh W; Stoughton RB
Arch Dermatol; 1976 Feb; 112(2):182-4. PubMed ID: 134675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
